{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:52:34Z","timestamp":1791604354371,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,7]],"date-time":"2027-09-07T00:00:00Z","timestamp":1820275200000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cllc.2026.08.007","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:08:43Z","timestamp":1787267323000},"page":"22-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3832-8274","authenticated-orcid":false,"given":"Troy J.","family":"Kleber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sage A.","family":"Copling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-4414","authenticated-orcid":false,"given":"C\u00e9sar P.","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waree","family":"Rinsurongkawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1667-6884","authenticated-orcid":false,"given":"Vadeerat","family":"Rinsurongkawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Jack","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1500-7083","authenticated-orcid":false,"given":"Yuliya","family":"Kitsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4578-9437","authenticated-orcid":false,"given":"Sherif M.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9303-962X","authenticated-orcid":false,"given":"Ivan","family":"Coronado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2224-9478","authenticated-orcid":false,"given":"Zhongxing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumil","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh-Nhu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Cascone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don L.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-156X","authenticated-orcid":false,"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara A.","family":"Vaporciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Rajaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza J.","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara B.","family":"Antonoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle G.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annikka","family":"Weissferdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3459-1833","authenticated-orcid":false,"given":"Julianna K.","family":"Bronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cllc.2026.08.007_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.007_bib0002","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.cllc.2026.08.007_bib0003","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cllc.2026.08.007_bib0004","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.cllc.2026.08.007_bib0005","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.007_bib0006","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative Toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cllc.2026.08.007_bib0007","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.annonc.2025.11.017","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial","volume":"37","author":"Wang","year":"2026","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17953","article-title":"Clinical outcomes of perioperative immunotherapy in resectable non-small cell lung cancer","volume":"8","author":"Desai","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.007_bib0009","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41392-025-02408-3","article-title":"Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial","volume":"10","author":"Qiu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"10.1016\/j.cllc.2026.08.007_bib0010","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.cllc.2026.08.007_bib0011","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cllc.2026.08.007_bib0012","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.007_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105123","article-title":"Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA","volume":"10","author":"Carbone","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2026.08.007_bib0014","article-title":"Immunotherapy for bilateral multiple ground glass opacities: an exploratory study for synchronous multiple primary lung cancer","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.007_bib0015","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cllc.2024.06.007","article-title":"MDT-BRIDGE: neoadjuvant Durvalumab plus chemotherapy followed by either surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in resectable or borderline-resectable stage IIB-IIIB NSCLC","volume":"25","author":"Reck","year":"2024","journal-title":"Clin Lung Cancer"},{"issue":"10 Supplement","key":"10.1016\/j.cllc.2026.08.007_bib0016","article-title":"EP.06G.09 harnessing real-world data for translational research in lung cancer: MD Anderson Thoracic GEMINI Program","volume":"19","author":"Zhang","year":"2024","journal-title":"Journal of Thoracic Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.007_bib0017","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.007_bib0018","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial","volume":"7","author":"Hui","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.007_bib0019","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/1759-7714.14273","article-title":"Postoperative radiotherapy improves survival of patients with ypN2 non-small cell lung cancer after neoadjuvant chemotherapy followed by surgery - A propensity score matching study of the Surveillance, Epidemiology, and End Results database","volume":"13","author":"Bao","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2026.08.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108061","article-title":"An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer","volume":"199","author":"Houda","year":"2025","journal-title":"Lung Cancer"},{"issue":"20","key":"10.1016\/j.cllc.2026.08.007_bib0021","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.cllc.2026.08.007_bib0022","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the Phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2026.08.007_bib0023","article-title":"Definitive radiotherapy with or without chemotherapy after planned neoadjuvant chemoimmunotherapy in stages II to III NSCLC: an international multicenter retrospective study","volume":"7","author":"Adib","year":"2026","journal-title":"JTO Clin Res Rep"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.007_bib0024","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ijrobp.2022.12.042","article-title":"Induction immune checkpoint inhibitors and chemotherapy before definitive chemoradiation therapy for patients with bulky unresectable stage III non-small cell lung cancer","volume":"116","author":"Wang","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2026.08.007_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1602082","article-title":"Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-institutional retrospective cohort study","volume":"16","author":"Fu","year":"2025","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.cllc.2026.08.007_bib0026","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.007_bib0027","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.athoracsur.2024.09.041","article-title":"The Society of Thoracic Surgeons Expert consensus on the multidisciplinary management and resectability of locally advanced non-small cell lung cancer","volume":"119","author":"Kim","year":"2025","journal-title":"Ann Thorac Surg"},{"issue":"9","key":"10.1016\/j.cllc.2026.08.007_bib0028","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.08.007_bib0029","doi-asserted-by":"crossref","first-page":"S1606","DOI":"10.1016\/j.annonc.2025.09.077","volume":"36","author":"Reck","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.08.007_bib0030","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.2147\/JIR.S484489","article-title":"Dose-volume constraints parameters for lung tissue in thoracic radiotherapy following immune checkpoint inhibitor treatment","volume":"17","author":"Wang","year":"2024","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.cllc.2026.08.007_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110040","article-title":"Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: a multi-institutional analysis","volume":"190","author":"Bi","year":"2024","journal-title":"Radiother Oncol"},{"issue":"10308","key":"10.1016\/j.cllc.2026.08.007_bib0032","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.007_bib0033","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.007_bib0034","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.014","article-title":"PL02.08 Perioperative vs Neoadjuvant Nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816","volume":"19","author":"Forde","year":"2024","journal-title":"J Thoracic Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.007_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1285","article-title":"Neoadjuvant-adjuvant vs Neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with resectable NSCLC: an indirect meta-analysis","volume":"7","author":"Zhou","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.007_bib0036","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.21037\/tlcr-2025-301","article-title":"Comparative investigation of neoadjuvant chemoimmunotherapy versus perioperative (chemo)immunotherapy in resectable non-small cell lung cancer: a real-world retrospective cohort study","volume":"14","author":"Yang","year":"2025","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.007_bib0037","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1186\/s12967-024-05727-1","article-title":"Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in NSCLC? A propensity score matching analysis","volume":"22","author":"Pan","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.cllc.2026.08.007_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.109389","article-title":"Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancer","volume":"215","author":"Lin","year":"2026","journal-title":"Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:24:39Z","timestamp":1791602679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1525730426001117"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}